Act A — The Dissolution Window
WHO prequalification is the international quality assessment that makes a manufacturer's product eligible for procurement by UN agencies, the Global Fund, and major international health programs. For a Nigerian manufacturer of metformin HCl tablets — first-line therapy for type 2 diabetes and essential for millions of patients across Africa — WHO prequalification opens procurement markets worth several times the manufacturer's current domestic sales.
The dissolution specification for metformin HCl tablets under WHO prequalification requirements is specific: not less than 80% dissolved at 30 minutes in 900 mL of water using USP Apparatus 2 at 50 rpm. The manufacturer's submission batches passed the 30-minute specification but failed at 15 minutes — a time point that WHO's dissolution acceptance criteria include for extended review assessment when the 15-minute specification is not met.
Halima has identified the likely mechanism: the current direct compression formulation uses a binder grade with a swelling rate that is creating a partial transport barrier at the tablet surface, slowing early dissolution without affecting the terminal profile. She has a hypothesis for the solution: switching to a lower-viscosity HPMC grade. What she does not have is certainty — changing the binder grade will require a new batch, a new dissolution study, and if the hypothesis is wrong, two months of development time are lost. She wants one conversation with a formulation specialist who has solved a similar dissolution issue in a metformin direct compression product before she commits to the approach.
Act B — The Story
Halima submitted a technical consultation request to the MarketForge pharmaceutical formulation collaboration platform. Her request: metformin HCl tablet direct compression, WHO prequalification dissolution failure at 15-minute time point, suspected binder-related transport barrier mechanism, seeking hypothesis confirmation and alternative approach input before committing to reformulation. Confidentiality framework: standard NDA terms required.
Dr. Paul spent twenty-two years in formulation development at a European generic pharmaceutical company, the last eight years as head of solid oral dosage form development. Metformin direct compression had been one of his most frequently encountered product categories — it is a high-volume essential medicine in every global generic manufacturer's portfolio, and its dissolution behaviour is sensitive to binder selection and compaction force in ways that are well-characterized in the literature but require experience to navigate in practice. He had registered on the platform after retiring, specifically to provide consultation on WHO prequalification technical challenges.
The platform matched Halima's request to Dr. Paul's profile. An NDA was executed digitally through the platform's document service before any formulation specifics were disclosed.
Their video session lasted 75 minutes. Dr. Paul confirmed Halima's binder hypothesis — the HPMC viscosity grade switch she was considering was appropriate, but he refined the approach: the switch needed to be accompanied by a reduction in compaction force because the lower-viscosity HPMC is more sensitive to over-compaction, which recreates the transport barrier through a different mechanism. He had seen that failure mode twice in his career. He also suggested the dissolution condition for the confirmation batch study: testing at three binder levels and two compaction forces concurrently to confirm the interaction effect before finalizing the specification, rather than testing the single experimental condition she had planned.
Halima adjusted the reformulation plan to include the factorial design he recommended. The confirmation batch study confirmed the interaction at the extreme compaction force condition — the exact failure mode Dr. Paul had flagged. The final formulation specification avoided it.
The WHO prequalification submission passed on the next assessment cycle.
Act C — Why This Market Stays Broken Without Infrastructure
Dr. Paul's experience with metformin direct compression dissolution failures was directly applicable to Halima's problem. He had seen the same failure mode twice, in different manufacturers' labs, and knew the secondary failure mechanism that Halima's planned experiment would not have caught. That knowledge — two cases, a decade apart, in a European manufacturing context — was applicable to her problem in Lagos without modification.
He had been retired for two years and had answered zero consultation requests because there was no mechanism that made Halima's specific technical question visible to him. The pharmaceutical consulting marketplace is organized around developed-country manufacturers and contract research organizations, not around collaborative access for African manufacturers at commercial scale.
Thin market infrastructure makes the technical specificity of Halima's question visible to the specialist who has answered exactly that question before — converting institutional knowledge that retirement would otherwise retire permanently into a resource for manufacturers solving the problems that determine whether African-manufactured medicines meet international quality standards.
Characters are fictional. WHO prequalification dissolution specifications for metformin HCl tablets, direct compression binder selection, and the WHO prequalification program are real. DeeperPoint is building the infrastructure this story describes.